Can compliance officers unring the bell?

Ideally, compliance officers are brought into their organization’s discussions about potential business deals at the outset to help ensure they start on a compliant path. Unfortunately, compliance officers are sometimes asked to assess the compliance risks of a proposed deal after the parties have already started discussions and negotiations. Naturally, once compliance officers become involved, they dutifully review the preliminary drafts, meeting minutes, PowerPoint presentations, etc., in an effort to assess potential compliance risks. Sometimes, compliance officers are stopped in their tracks because they uncover what appears to be a “smoking gun”—evidence that the parties are motivated to do the proposed deal because of the resulting referrals, thus potentially jeopardizing compliance with the federal Anti-Kickback Statute (AKS). Among other things, the AKS prohibits the knowing and willful offer, payment, solicitation, or receipt of remuneration, directly or indirectly, overtly or covertly, in cash or in-kind, as inducement for the referral of patients for items or services for which payment may be made in whole or in part under a federal healthcare program and any state healthcare program.[1]

When this happens, a crucial decision must be made based on an assessment of whether the deal is sufficiently tainted that it must be called off or whether, instead, there is a way to fully address the issues raised by the evidence uncovered and put the deal on a compliant path forward (i.e., “unring” the bell). This article offers some suggestions to help guide compliance officers through that decision-making process.

This document is only available to members. Please log in or become a member.
 


Would you like to read this entire article?

If you already subscribe to this publication, just log in. If not, let us send you an email with a link that will allow you to read the entire article for free. Just complete the following form.

* required field